As per reports, the Canadian health regulator has approved Johnson & Johnson (JNJ) to import its COVID-19 vaccine manufactured at Emergent BioSolutions Inc’s plant in Baltimore, Maryland. The decision came after Health Canada completed an inspection of the facility, along with the European Medicines Agency and South African Health Products Regulatory Authority. All three regulators found the facility to be compliant with good manufacturing practices.
Operations at Emergent’s facility were put on hold by the U.S. Food and Drug Administration after J&J’s Covid -19 vaccine was found to be contaminated with material from AstraZeneca’s COVID-19 shots, which were also being produced in the facility at the same time. In June, Canada refused to accept any doses made at the Emergent facility until its inspection.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
